In 2025, Fosun Pharma conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Waste Generated | 48,813a | 59,490a | 56,029a | |
Total Waste Recovered | N/A | N/A | N/A | |
Total Hazardous Waste Generated | 12,781a | 10,950a | 9,618a | |
Non-Hazardous Waste Disposed | 36,032a | N/A | N/A |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, Fosun Pharma generated a total of 48,813 metric tonnes of waste.a
Of this amount, 26.18% of Fosun Pharma's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.73.82% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.a
Since 2019, Fosun Pharma's total waste generation decreased by 33.63%, with an additional 17.95% decline in 2025, suggesting a consistent and deliberate effort to minimize waste generation at the source.a
Over the same period, the share of hazardous waste in Fosun Pharma's total output increased by 345.67%, including a further 42.25% rise in 2025, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.a
Overall, Fosun Pharma's waste and hazardousness trends are mixed or inconclusive. A more detailed review of its materials, industry standards, and operational changes would help clarify the net environmental impact of its waste strategy.a